Pouchitis: Lessons for inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 25, Issue 4, 2009, Pages 314-322

  Wu, Hao ^a   Shen, Bo ^b  

^a FUDAN UNIVERSITY   (China)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Classification; Complication; Ileal pouch; Inflammatory bowel disease; Pathogenesis; Pouchitis; Restorative proctocolectomy

Indexed keywords

BACTERIAL ANTIGEN; CIPROFLOXACIN; INTERLEUKIN 17; INTERLEUKIN 23; METRONIDAZOLE; NEUTROPHIL CYTOPLASMIC ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; CAMPYLOBACTER ENTERITIS; CANDIDA ALBICANS; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; DRUG USE; ENDOTHELIAL DYSFUNCTION; ENTERITIS; ESCHERICHIA COLI; EVOLUTION; FECES CULTURE; FECES MICROFLORA; HEREDITY; HOST PATHOGEN INTERACTION; HOST SUSCEPTIBILITY; HUMAN; ILEITIS; ILEOSTOMY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INCIDENCE; INFECTION; INFLAMMATION; INNATE IMMUNITY; INTESTINE METAPLASIA; ISCHEMIA; LACTOBACILLUS; MICROBIAL COMMUNITY; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PROCTOCOLECTOMY; PROTEIN EXPRESSION; PSEUDOMONAS; REVIEW; RISK FACTOR; SACCHAROMYCES CEREVISIAE; SALMONELLA TYPHI; THROMBOCYTOSIS; ULCERATIVE COLITIS;

ANIMALS; ANTI-BACTERIAL AGENTS; COLONIC POUCHES; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; POUCHITIS; PROCTOCOLECTOMY, RESTORATIVE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REOPERATION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 68049097210     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32832b36eb     Document Type: Review

References (114)

1. Dhillon S, Loftus EV Jr, Tremaine WJ, et al. The natural history of surgery for ulcerative colitis in a population-based cohort from Olmsted County, Minnesota. Am J Gastroenterol 2005; 100:A819.
2. Shen B, Fazio VW, Lashner BA, et al. Comprehensive evaluation of inflammatory and non-inflammatory sequelae of ileal pouch-anal anastomosis. Am J Gastroenterol 2005; 100:93-101. (Pubitemid 41623275)
3. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007; 13:254-261.
4. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind placebo controlled trial. Gastroenterology 2003; 124:1202-1209. (Pubitemid 36531796)
5. Abdelrazeq AS, Kandiyil N, Botterill ID, et al. Predictors for acute and chronic pouchitis following restorative proctocolectomy for ulcerative colitis. Colorectal Dis 2008; 10:805-813.
6. Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996; 38:234-239. (Pubitemid 26046819)
7. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomosis complications and function in 1005 patients. Ann Surg 1995; 222:120-127.
8. Ferrante M, Declerck S, De Hertogh G, et al. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis 2008; 14:20-28. (Pubitemid 351196864)
9. Fleshner P, Ippoliti A, Dubinsky M, et al. Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2008; 6:561-568. Serum antibodies to bacterial antigens were studied to investigate bacteria-host interaction in pouchitis.
10. Stocchi L, Pemberton JH. Pouch and pouchitis. Gastroenterol Clin North Am 2001; 30:223-241.
11. Schmidt CM, Lazenby AJ, Hendrickson RJ, Sitzmann JV. Preoperative terminal ileal and colonic resection histopathology predicts risk of pouchitis in patients after ileoanal pull-through procedure. Ann Surg 1998; 227:654-662.
12. Achkar JP, Al-Haddad M, Lashner B, et al. Differentiating risk factors for acute and chronic pouchitis. Clin Gastroenterol Hepatol 2005; 3:60-66. (Pubitemid 40092945)
13. Okon A, Dubinsky M, Vasilauskas EA, et al. Elevated platelet count before ileal pouch-anal anastomosis for ulcerative colitis is associated with the development of chronic pouchitis. Am Surg 2005; 71:821-826.
14. Shepherd NA, Hulten L, Tytgat GNJ. Workshop: pouchitis. Int J Colorectal Dis 1989; 4:205-229.
15. Hata K, Watanabe T, Shinozaki M, Nagawa H. Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis: multivariate analysis. Scand J Gastroenterol 2003; 38:1055-1058. (Pubitemid 37352469)
16. Lepistö A, Kärkkäinen P, Järvinen HJ. Prevalence of primary sclerosing cholangitis in ulcerative colitis patients undergoing proctocolectomy and ileal pouch-anal anastomosis. Inflamm Bowel Dis 2008; 14:775-779.
17. Fleshner PR, Vasiliauskas EA, Kam LY, et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 2001; 49:671-677.
18. Kuisma J, Jarvinen H, Kahri A, Farkkilla M. Factors associated with disease activity of pouchitis after surgery for ulcerative colitis. Scand J Gastroenterol 2004; 39:544-548. (Pubitemid 38916259)
19. Shen B, Fazio VW, Remzi FH, et al. Risk factors for diseases of ileal pouch-anal anastomosis in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4:81-89. (Pubitemid 43129528)
20. Hui T, Landers C, Vasiliauskas E, et al. Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. Dis Colon Rectum 2005; 48:1254-1262. (Pubitemid 40897873)
21. Fleshner P, Ippoliti A, Dubinsky M, et al. A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2007; 5:952-958. (Pubitemid 47127022)
22. Hoda KM, Collins JF, Knigge KL, Deveney KE. Predictors of pouchitis after ileal pouch-anal anastomosis: a retrospective review. Dis Colon Rectum 2008; 51:554-560.
23. Atila K, Terzi C, Canda AE, et al. Partially hydrolyzed guar gum attenuates the severity of pouchitis in a rat model of ileal J pouch-anal anastomosis. Dig Dis Sci 2009; 54:522-529.
24. Chen CN, McVay LD, Batlivala ZS, et al. Anatomic and functional characteristics of the rat ileal pouch. Am J Surg 2002; 183:464-470.
25. Penna C, Tiret E, Kartheuser A, et al. Function of ileal J pouch-anal anastomosis in patients with familial adenomatous polyposis. Br J Surg 1993; 80:765-767. (Pubitemid 23197736)
26. Tjandra JJ, Fazio VW, Church JM, et al. Similar functional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. Am J Surg 1993; 165:322-325.
27. Shen B, Remzi FH, Hammel JP, et al. Family history of Crohn's disease is associated with an increased risk for Crohn's disease of ileal pouch-anal anastomosis. Inflamm Bowel Dis 2009; 15:163-170.
28. Melmed GY, Fleshner PR, Bardakcioglu O, et al. Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2008; 51:100-108.
29. Carter K, Di Giovine FS, Cox A, et al. The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. Gastroenterology 2001; 121:805-811. (Pubitemid 32959391)
30. Brett PM, Yasuda N, Yiannakou JY, et al. Genetic and immunological markers in pouchitis. Euro J Gastroenterol Hepatol 1996; 8:951-955.
31. Aisenberg J, Legnani PE, Nilubol N, et al. Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis. Am J Gastroenterol 2004; 99:432-441. (Pubitemid 38524119)
32. Meier C, Hegazi RA, Aisenberg J, et al. Innate immune receptor genetic polymorphisms in pouchitis: is NOD2/CARD15 a susceptibility factor? Inflamm Bowel Dis 2005; 11:965-971.
33. Lammers KM, Ouburg S, Morre SA, et al. Combined carriership of TLR9-1237C and CD14-260T alleles enhances the risk for developing chronic relapsing pouchitis. World J Gastroenterol 2005; 11:7323-7329. (Pubitemid 43137684)
34. Duffy M, O'Mahony L, Coffey JC, et al. Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial adenomatous polyposis. Dis Colon Rectum 2002; 45:384-388. (Pubitemid 34273621)
35. Nasmyth DG, Godwin PGR, Dixon MF, et al. Ileal ecology after pouch anal anastomosis or ileostomy. Gastroenterology 1989; 96:817-824.
36. Komanduri S, Gillevet PM, Sikaroodi M, et al. Dysbiosis in pouchitis: evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol 2007; 5:352-360. This paper is the first to systemically study the bacterial profile using advanced molecular micriobiological technology. (Pubitemid 46401536)
37. Sokol H, Lay C, Seksik P, Tannock GW. Analysis of bacterial bowel communities of IBD patients: what has it revealed? Inflamm Bowel Dis 2008; 14:858-867. This review article listed advances and challenges in studying gut bacterial community in IBD and pouchitis.
38. Shen B, Jiang Z-D, Fazio VW, et al. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol 2008; 6:782-788. The high prevalence of C. difficile infection in patients with ileal pouches raises awareness of the role of this bacterial pathogen in pouchitis.
39. Munoz-JuarezM, Pemberton JH, Sandborn WJ, et al. Misdiagnosis of specific cytomegalovirus infection of ileoanal pouch as a refractory idiopathic chronic pouchitis. Report of two cases. Dis Colon Rectum 1999; 42:117-120.
40. Mooka D, Furth EE, MacDermott RP, Lichtenstein GR. Pouchitis associated with primary cytomegalovirus infection. Am J Gastroenterol 1998; 93:264-266. (Pubitemid 29063981)
41. Kühbacher T, Ott SJ, Helwig U, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 2006; 55:833-841. (Pubitemid 43764555)
42. Ohge H, Furne JK, Springfield J, et al. Association between fecal hydrogen sulfide production and pouchitis. Dis Colon Rectum 2005; 48:469-475. (Pubitemid 40767867)
43. Gosselink MP, Schouten WR, van Lieshout LM, et al. Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis Colon Rectum 2004; 47:1519-1525.
44. Ruseler-van Embden JG, Schouten WR, van Lieshout LM. Pouchitis: result of microbial imbalance? Gut 1994; 35:658-664.
45. Falk A, Olsson C, Ahrne S, et al. Ileal pelvic pouch microbiota from two former ulcerative colitis patients, analysed by DNA-based methods, were unstable over time and showed the presence of Clostridium perfringens. Scand J Gastroenterol 2007; 42:973-985. (Pubitemid 47037119)
46. Shen B, Remzi FH, Lavery IC, et al. A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy. Clin Gastroenterol Hepatol 2008; 6:145-148. This article provides a systemic classification of ileal pouch-associated disorders and conditions, which may help in the diagnosis, differential diagnosis, treatment, and prediction of treatment outcome. (Pubitemid 351172940)
47. Andersone AF, Lindberg M, Jakobsson H, et al. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS One 2008; 3:e2836.
48. Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. Nature 2007; 449:804-810.
49. Kroesen AJ, Leistenschneider P, Lehmann K, et al. Increased bacterial permeation in long-lasting ileoanal pouches. Inflamm Bowel Dis 2006; 12:736-744. (Pubitemid 44253758)
50. DeSilva HJ, Jones M, Prince C, et al. Lymphocyte and macrophage subpopulations in pelvic ileal reservoirs. Gut 1991; 32:1160-1165.
51. Hirata I, Berrebi G, Austin LL, et al. Immunohistological characterization of intraepithelial and lamina propria lymphocytes in control ileum and colon and inflammatory bowel disease. Dig Dis Sci 1986; 31:593-603. (Pubitemid 16064013)
52. Stallmach A, Schafer F, Hoffman S, et al. Increased state of activation of CD4 positive T cells and elevated interferon gamma production in pouchitis. Gut 1998; 43:499-505. (Pubitemid 28462035)
53. Thomas PD, Forbes A, Nicholls RJ, Ciclitira P. Altered expression of the lymphocyte activation markers CD30 and CD27 in patients with pouchitis. Scand J Gastroenterol 2001; 36:258-264. (Pubitemid 32234574)
54. Goldberg PA, Herbst F, Beckett CG, et al. Leukocyte typing, cytokine expression and epithelial turn over in the ileal pouch in patients with ulcerative colitis and familial adenomatous polyposis. Gut 1996; 38:549-553. (Pubitemid 26112751)
55. Kroesen AJ, Dullat S, Schulzke JD, et al. Permanently increased mucosal permeability in patients with backwash ileitis after ileoanal pouch for ulcerative colitis. Scand J Gastroenterol 2008; 43:704-711. (Pubitemid 351868710)
56. Toiyama T, Araki T, Yoshiyama S, et al. The expression patterns of Toll-like receptors in the ileal pouch mucosa of postoperative ulcerative colitis patients. Surgery Today 2006; 36:287-290. (Pubitemid 43288728)
57. Heuschen G, Leowardi C, Hinz U, et al. Differential expression of toll-like receptor 3 and 5 in ileal pouch mucosa of ulcerative colitis patients. In J Colorectal Dis 2007; 22:293-301. (Pubitemid 46071107)
58. Kelsall BL, Leon F. Involvement of intestinal dendritic cells in oral tolerance, immunity to pathogens, and inflammatory bowel disease. Immunol Rev 2005; 206:132-148. (Pubitemid 41105167)
59. Morel PA, Feili-Hariri M, Coates PT, et al. Dendritic cells, T cell tolerance and therapy of adverse immune reactions. Clin Exp Immunol 2003; 133:1-10.
60. Ayabe T, Satchell DP, Wilson CL, et al. Secretion of microbicidal alphadefensins by intestinal Paneth cells in response to bacteria. Nat Immunol 2000; 1:113-118.
61. Salzman NH, Ghosh D, Huttner KM, et al. Protection against enteric Salmonellosis in transgenic mice expressing a human intestinal defensin. Nature 2003; 422:522-526. (Pubitemid 36433647)
62. Ouellette A, Bevins CL. Paneth cell defensins and innate immunity of the small bowel. Inflam Bowel Dis 2001; 7:43-50.
63. Porter EM, Bevins CL, Ghosh D, Ganz T. The multifaceted Paneth cell. Cell Mol Life Sci 2002; 59:156-170.
64. Ghosh D, Porter EM, Shen B, et al. Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol 2002; 3:583-590. (Pubitemid 34662312)
65. Porter E, van Dam E, Valore E, Ganz T. Broad spectrum antimicrobial activity of human intestinal defensin 5. Infect Immun 1997; 65:2396-2401. (Pubitemid 27237326)
66. Wehkamp J, Salzman NH, Porter E, et al. Decreased Paneth cell defensins and antimicrobial activity in ileal Crohn's disease. Proc Natl Acad Sci U S A 2005; 102:18129-18134. (Pubitemid 41798513)
67. Kiehne K, Brunke G, Wegner F, et al. Defensin expression in chronic pouchitis in patients with ulcerative colitis or familial adenomatous polyposis coli. World J Gastroenterol 2006; 12:1056-1062.
68. Möndel M, Schroeder BO, Zimmermann K, et al. Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. Mucosal Immunol 2009; 2:166-172.
69. Khazen D, Jendoubi-Ayed S, Aleya WB, et al. Polymorphism in ICAM-1, PECAM-1, E-selectin, and L-selectin genes in Tunisian patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2009; 21:167-175.
70. Thomas PD, Forbes A, Price AB, et al. Differential expression of cell adhesion molecules within inflamed ileal pouch mucosa: relationship to recruited cell subtypes. Eur J Gastroenterol Hepatol 2002; 14:137-144. (Pubitemid 34163992)
71. Miner P Jr, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 2004; 19:281-286. (Pubitemid 38253502)
72. Hirata N, Oshitani N, Kamata N, et al. Proliferation of immature plasma cells in pouchitis mucosa in patients with ulcerative colitis. Inflamm Bowel Dis 2008; 14:1084-1090.
73. Patel RT, Bain I, Youngs D, Keighley MRB. Cytokine production in pouchitis is similar to that in ulcerative colitis. Dis Colon Rectum 1995; 38:831-837.
74. Schmidt C, Giese T, Ludwig B, et al. Increased cytokine transcripts in pouchitis reflect the degree of inflammation but not the underlying entity. Int J Colorectal Dis 2006; 21:419-426.
75. Gionchetti P, Campieri M, Belluzzi A, et al. Mucosal concentrations of interleukin-1b, interleukin-6, interleukin-8, and tumor necrosis factor-a in pelvic ileal pouches. Dig Dis Sci 1994; 39:1525-1531. (Pubitemid 2120471)
76. Bulois P, Tremaine WJ, Maunoury V, et al. Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10. Inflamm Bowel Dis 2000; 6:157-164.
77. Patel RT, Pall AA, Adu D, Keighley MRB. Circulating soluble adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995; 7:1037-1041. (Pubitemid 26014458)
78. Chaussade S, Denizot Y, Valleur P, et al. Presence of PAF-acether in stool of patients with pouch ileoanal anastomosis and pouchitis. Gastroenterology 1991; 100:419-423.
79. Gertner DJ, Rampton DS, Madden MV, et al. Increased leukotriene B4 release from ileal pouch mucosa in ulcerative colitis compared with familial adenomatous polyposis. Gut 1994; 35:1429-1432. (Pubitemid 2128528)
80. Romano M, Cuomo A, Tuccillo C, et al. Vascular endothelial growth factor and cyclooxygenase-2 are overexpressed in ileal pouch-anal anastomosis. Dis Colon Rectum 2007; 50:650-659. (Pubitemid 46870462)
81. Stucchi AF, Shebani KO, Leeman SE, et al. A neurokinin 1 receptor antagonist reduces an ongoing ileal pouch inflammation and the response to a subsequent inflammatory stimulus. Am J Physiol Gastrointest Liver Physiol 2003; 285:G1259-G1267.
82. Stallmach A, Chan CC, Ecker K-W, et al. Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut 2000; 47:415-422. (Pubitemid 30670838)
83. Ulisse S, Gionchetti P, Alo S, et al. Expression of cytokine, inducible nitric oxide synthase, matrix metalloproteinases in pouchitis: effects of probiotic therapy. Am J Gastroenterol 2001; 96:2691-2696. (Pubitemid 32889207)
84. Leal RF, Coy CS, Ayrizono ML, et al. Differential expression of pro-inflammatory cytokines and a pro-apoptotic protein in pelvic ileal pouches for ulcerative colitis and familial adenomatous polyposis. Tech Coloproctol 2008; 12:33-38.
85. Thomas PD, Forbes A, Nicholls RJ, Ciclitira PJ. Increased mucosal IFN-γ production in pouchitis despite normal functional responses of isolated CD4 cells. Gut 1999; 44 (Suppl 4):32A.
86. Kobayashi T, Okamoto S, Hisamatsu T, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 2008; 57:1682-1689.
87. Bell AJ, Nicholls RJ, Forbes A, et al. Human lymphocyte stimulation with pouchitis flora is greater than with flora from a healthy pouch but is suppressed by metronidazole. Gut 2004; 53:1801-1805. (Pubitemid 39556900)
88. Sandborn W. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 1994; 107:1856-1860. (Pubitemid 124006527)
89. Gosselink MP, Schouten WR, van Lieshout LMC, et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004; 47:876-884.
90. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305-309. (Pubitemid 30621980)
91. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3®) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53:108-114. (Pubitemid 38083018)
92. Pronio A, Montesani C, Butteroni C, et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 2008; 14:662-668. (Pubitemid 351742983)
93. Chaussade S, Denizot Y, Valleur P, et al. Presence of PAF-acether in stool of patients with pouch ileoanal anastomosis and pouchitis. Gastroenterology 1991; 100:419-423.
94. Shepherd NA, Healey CJ, Warren BF, et al. Distribution of mucosal morphology and an assessment of colonic phenotype change in the pelvic ileal reservoir. Gut 1993; 34:101-105.
95. Biancone L, Palmieri G, Lombardi A, et al. Tropomyosin expression in the ileal pouch: a relationship with the development of pouchitis in ulcerative colitis. Am J Gastroenterol 2003; 98:2719-2726. (Pubitemid 38020114)
96. Tysk C, Riedesel H, Lindberg E, et al. Colonic glycoproteins in monozygote twins with inflammatory bowel disease. Gastroenterology 1991; 100:1509-1514.
97. Merrett MN, Soper N, Mortensen N, Jewell DP. Intestinal permeability in the ileal pouch. Gut 1996; 39:226-230.
98. Lohmuller JL, Pemberton HJ, Dozois RR, et al. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg 1990; 211:622-629.
99. Merrett MN, Mortensen N, Kettlewell M, Jewell DO. Smoking may prevent pouchitis in patients with restorative proctocolectomy for ulcerative colitis. Gut 1996; 38:362-364. (Pubitemid 26074315)
100. Hatoum OA, Binion DG, Otterson MF, Gutterman DD. Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology 2003; 125:58-69.
101. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009; 136:585-595.
102. Thirlby RC. Optimizing results and techniques of mesenteric lengthening in ileal pouch-anal anastomosis. Am J Surg 1995; 169:499-502.
103. Cherqui D, Valleur P, Perniceni T, et al. Inferior reach of ileal reservoir in ileoanal anastomosis: experimental anatomic and angiographic study. Dis Colon Rectum 1987; 30:365-371. (Pubitemid 17078521)
104. Kienle P, Weitz J, Reinshagen S, et al. Association of decreased perfusion of the ileoanal pouch mucosa with early postoperative pouchitis and local septic complications. Arch Surg 2001; 136:1124-1130. (Pubitemid 32929338)
105. Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg 2000; 24:851-856.
106. Laake KO, Line PD, Grzyb K, et al. Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a J-configurated ileal-pouch-anal-anastomosis (IPAA). Scand J Gastroenterol 2004; 39:1228-1235. (Pubitemid 39656838)
107. Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implication for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990; 87:1620-1624. (Pubitemid 20080360)
108. Joelsson M, Andersson M, Bark T, et al., Swedish Organization for the Study of Inflammatory Bowel Diseases. Allopurinol as prophylaxis against pouchitis following ileal pouch-anal anastomosis for ulcerative colitis. A randomized placebo-controlled double-blind study. Scand J Gastroenterol 2001; 36:1179-1184.
109. El Muhtaseb MS, Talwar D, Duncan A, et al. Free radical activity and lipid soluble antioxidant vitamin status in patients with long-term ileal pouch-anal anastomosis. Colorectal Dis 2009; 11:67-72.
110. Shebani KO, Stucchi AF, McClung JP, et al. Role of stasis and oxidative stress in ileal pouch inflammation. J Surg Res 2000; 90:67-75.
111. Levin KE, Pemberton JH, Phillips SF, et al. Role of oxygen free radicals in the etiology of pouchitis. Dis Colon Rectum 1992; 35:452-456.
112. Weng X, Liu L, Barcellos LF, et al. Clustering of inflammatory bowel disease with immune mediated diseases among members of a Northern California-managed care organization. Am J Gastroenterol 2007; 102:1429-1435. (Pubitemid 46976291)
113. Schaus BJ, FazioVW,Remzi FH, et al. Large polyps in the ileal pouch in patients with underlying ulcerative colitis. Dis Colon Rectum 2006; 50:832-838.
114. Shen L, Lian L, Goldblum JR, Remzi FH. Development of de novo celiac disease after restorative proctocolectomy and ileal pouch-anal anastomosis. Inflamm Bowel Dis 2008. [Epub ahead of print]